Lakewood-Amedex Stock Price, News & Analysis
Company Description
Lakewood-Amedex (NASDAQ: LABT) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $54.5M, ranking #5,638 among all listed U.S. companies by market cap.
LABT stock has declined 69.3% over the past year. Shares last traded at $3.59.
This page provides a comprehensive overview of LABT stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Lakewood-Amedex (LABT) stock last traded at $3.59, down 23.40% from the previous close. Over the past 12 months, the stock has lost 69.3%. At a market capitalization of $54.5M, LABT is classified as a micro-cap stock with approximately 7.0M shares outstanding.
LABT Rankings
Latest News
Lakewood-Amedex has 2 recent news articles, with the latest published 2 days ago. Of the recent coverage, 1 article coincided with positive price movement and 0 with negative movement. Key topics include management. View all LABT news →
SEC Filings
Lakewood-Amedex has filed 4 recent SEC filings, including 1 Form 424B3, 1 Form 8-K, 1 Form 424B4, 1 Form CERT. The most recent filing was submitted on April 30, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LABT SEC filings →
Financial Highlights
Upcoming Events
Initiate Phase 2a trial
Lakewood-Amedex has 1 upcoming scheduled event. The next event, "Initiate Phase 2a trial", is scheduled for May 1, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the LABT stock price.
Short Interest History
Days to Cover History
LABT Company Profile & Sector Positioning
Lakewood-Amedex (LABT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.